FDA seeks evidence from another study of motavizumab

08/30/2010 | Wall Street Journal, The

MedImmune received a second complete-response letter from the FDA for motavizumab, an experimental drug to prevent serious respiratory syncytial virus. The agency asked for clinical data from an additional study that supports a "satisfactory risk/benefit profile in the population for which the prophylaxis indication is being requested."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA